As we all know, Vanke is a benchmark company that cannot be avoided by research in the real estate industry.

2025/06/0503:17:33 finance 1819

As we all know, Vanke is a benchmark enterprise that cannot be avoided by research in the real estate industry.

Today, Vanke's operating income, net profit, shareholders' equity, return on assets and other data from 2011 to 2021, and share it with you:

operating income change trend

As we all know, Vanke is a benchmark company that cannot be avoided by research in the real estate industry. - DayDayNews

Vanke's revenue change trend

over the years 3

From the above figure, Vanke's revenue in 2011 was 71.8 billion yuan. During the period of 2021, it maintained a positive growth in operating income for 11 consecutive fiscal years, reaching 452.8 billion yuan in 2021, 6.3 times that of 2011. Vanke successfully ranked among the top 500: in 2016, with its revenue of 185.5 billion yuan in 2015; in 2022, Fortune ranked 178th.

net profit change trend

As we all know, Vanke is a benchmark company that cannot be avoided by research in the real estate industry. - DayDayNews

Vanke's net profit change trend

Regarding the changes in Vanke's net profit, we can see from the above figure that except for the special market background in 2021, Vanke's net profit declined, the other 10 fiscal years maintained positive growth in net profit, with a net profit of 9.6 billion yuan in 2011, and a net profit peak of 41.5 billion yuan in 2020, and a sharp decline in 22.5 billion yuan in 2021. In the 11 years from 2011 to 2021, Vanke made a cumulative net profit of 256.5 billion yuan, which is far higher than today's Vanke's market value (the market value of 188.1 billion yuan after the closing on October 19).

shareholder equity change trend

As we all know, Vanke is a benchmark company that cannot be avoided by research in the real estate industry. - DayDayNews

shareholder equity

Look at the picture, Vanke's shareholder equity in 2011 was only 52.9 billion yuan, while in 2021, shareholder equity reached 235.9 billion yuan, corresponding to the above-mentioned market value of 188.1 billion yuan, the assets undervalued by about 20% (equivalent to a 20% discount on net assets per share).

Network equity rate hiccups Changes trend

Real estate industry is a capital-intensive industry, and every project pursues high leverage of funds, thereby amplifying the rate of return on net assets.

As we all know, Vanke is a benchmark company that cannot be avoided by research in the real estate industry. - DayDayNews

Network Assets

As can be seen from the above figure, except for 2021, Vanke's return on assets steadily slides between 17% and 21% in the other 10 fiscal years, with a low of 17.8% (2014) and a high of 21.6% (2018), but there have been significant changes in 2021, with a decline of 9.5%, which is below 10% for the first time in 10 years.

Attached Comprehensive Table

As we all know, Vanke is a benchmark company that cannot be avoided by research in the real estate industry. - DayDayNews

Main indicators Comprehensive

The current guiding principles for the real estate market are still housing for living, not for speculation, renting and purchasing, and market entities have the possibility of further concentration into the leader.

For Vanke, what do you want to say? Welcome to leave a message to interact.

finance Category Latest News

According to data from Juchao Information Network, in the past two and a half years, Kanghong Pharmaceutical has disclosed nearly 80 announcements about using its own funds to purchase financial management, that is, there are an average of two to three announcements about purchas - DayDayNews

According to data from Juchao Information Network, in the past two and a half years, Kanghong Pharmaceutical has disclosed nearly 80 announcements about using its own funds to purchase financial management, that is, there are an average of two to three announcements about purchas

Behind Kanghong Pharmaceutical's "crazy" buying financial management: its stock price was "cut down" in less than three years, its important product Kangbocept "goes overseas" and its stranded in Europe and the United States, resulting in more than 1 billion yuan was wasted, and